Publications based on CRC1479 funding

Kreutmair S, Lippert LJ, Klingeberg C, Albers-Leischner C, Yacob S, Shlyakhto V, Mueller T, Mueller-Rudorf A, Yu C, Gorantla SP, Miething C, Duyster J, Illert AL. NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis. Front Oncol. 2022 May 13;12:875117. doi: 10.3389/fonc.2022.875117.

Fröhlich K, Brombacher E, Fahrner M, Vogele D, Kook L, Pinter N, Bronsert P, Timme-Bronsert S, Schmidt A, Bärenfaller K, Kreutz C, Schilling O. Benchmarking of analysis strategies for data-independent acquisition proteomics using a large-scale dataset comprising inter-patient heterogeneity. Nat Commun. 2022 May 12;13(1):2622. doi: 10.1038/s41467-022-30094-0.

Pinter N, Glätzer D, Fahrner M, Fröhlich K, Johnson J, Grüning BA, Warscheid B, Drepper F, Schilling O, Föll MC. MaxQuant and MSstats in Galaxy Enable Reproducible Cloud-Based Analysis of Quantitative Proteomics Experiments for Everyone. J Proteome Res. 2022 May 3. doi: 10.1021/acs.jproteome.2c00051.

Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, Del Gaudio F, He L, Paterson N, Nent E, Fernández-Klett F, Yamasaki A, Frosch M, Fliegauf M, Bosch LFP, Ulupinar H, Hagemeyer N, Schreiner D, Dorrier C, Tsuda M, Grothe C, Joutel A, Daneman R, Betsholtz C, Lendahl U, Knobeloch KP, Lämmermann T, Priller J, Kierdorf K, Prinz M. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature. 2022 Apr;604(7907):740-748. doi: 10.1038/s41586-022-04596-2. Epub 2022 Apr 20. Erratum in: Nature. 2022 Oct;610(7930):E1.

Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D’Alessio A, Pinato DJ, Bettinger D, Binder H, John Wherry E, Schultheiss M, Thimme R, Bengsch B. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol. 2022 Aug;77(2):397-409. doi: 10.1016/j.jhep.2022.02.032. Epub 2022 Apr 1. 

Zeiser R, Lee SJ. Three FDA-approved therapies for chronic GVHD. Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448. 

Flum M, Dicks S, Teng YH, Schrempp M, Nyström A, Boerries M, Hecht A. Canonical TGFβ signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene. 2022 Mar;41(10):1492-1506. doi: 10.1038/s41388-022-02190-4.

Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, Buettner F, Conche C, Petrocelli V, Elwakeel E, Weigert A, Zinoveva A, Fleischmann M, Häupl B, Karakütük C, Bohnenberger H, Mosa MH, Kaderali L, Gaedcke J, Ghadimi M, Rödel F, Arkan MC, Oellerich T, Rödel C, Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022 Feb 14;40(2):168-184.e13. doi: 10.1016/j.ccell.2022.01.004.

Harder I, Münchhalfen M, Andrieux G, Boerries M, Grimbacher B, Eibel H, Maccari ME, Ehl S, Wienands J, Jellusova J, Warnatz K, Keller B. Dysregulated PI3K Signaling in B Cells of CVID Patients. Cells. 2022 Jan 28;11(3):464. doi: 10.3390/cells11030464.

Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJ, Meyers G, Ghosh M, Deeren D, Sanz J, Morariu-Zamfir R, Arbushites M, Lakshminarayanan M, Barbour AM, Chen YB. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022 Jan;9(1):e14-e25.doi: 10.1016/S2352-3026(21)00367-7.

highlighted by this Editorial: Paczesny S. Graft-versus-host disease treatment beyond corticosteroids in newly diagnosed patients? Lancet Haematol. 2022 Jan;9(1):e2-e3. doi: 10.1016/S2352-3026(21)00376-8. PMID: 34971578.

Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Boerries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021 Dec 20;19(1):123. doi: 10.1186/s12964-021-00801-3.

Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. Epub 2021 Dec 13.2021

Zeiser R, Teshima T. Non-classical manifestations of acute GVHD. Blood. 2021 Dec 2;138(22):2165-2172. doi: 10.1182/blood.2021012431. 

Braun LM, Zeiser R. Kinase Inhibition as Treatment for Acute and Chronic Graft- Versus-Host Disease. Front Immunol. 2021 Nov 17;12:760199. doi: 10.3389/fimmu.2021.760199.

El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021 Nov 8;12(1):6436. doi: 10.1038/s41467-021-26683-0.

Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O’Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021 Oct 28;184(22):5577-5592.e18. doi: 10.1016/j.cell.2021.09.022. Epub 2021 Oct 12.2021.

Vinnakota JM, Zeiser R. Acute Graft- Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System. Front Immunol. 2021 Oct 6;12:748019. doi: 10.3389/fimmu.2021.748019.

Hoefflin R, Harlander S, Abhari BA, Peighambari A, Adlesic M, Seidel P, Zodel K, Haug S, Göcmen B, Li Y, Lahrmann B, Grabe N, Heide D, Boerries M, Köttgen A, Heikenwalder M, Frew. Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Sep 25;13(19):4801. doi: 10.3390/cancers13194801.

Bernasconi R, Thriene K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth AC, Stumpe M, Kiritsi D, Martin SF, Hinz B, Bruckner-Tuderman L, Dengjel J, Nyström A. 2021. Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7). EMBO Mol Med. 2021 e14392. doi: 10.15252/emmm.202114392.

Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021 Sep;21(9):541-557. doi: 10.1038/s41568-021-00383-9.